These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2893655)

  • 1. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
    De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
    Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
    Dawbarn D; De Quidt ME; Emson PC
    Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET.
    Boecker H; Ceballos-Baumann A; Bartenstein P; Weindl A; Siebner HR; Fassbender T; Munz F; Schwaiger M; Conrad B
    Brain; 1999 Sep; 122 ( Pt 9)():1651-65. PubMed ID: 10468505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
    Grafe MR; Forno LS; Eng LF
    J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E; Beal MF
    Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease.
    Utal AK; Stopka AL; Roy M; Coleman PD
    Neuroscience; 1998 Oct; 86(4):1055-63. PubMed ID: 9697113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin is increased in the basal ganglia in Huntington disease.
    Aronin N; Cooper PE; Lorenz LJ; Bird ED; Sagar SM; Leeman SE; Martin JB
    Ann Neurol; 1983 May; 13(5):519-26. PubMed ID: 6191621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.
    Bartzokis G; Tishler TA
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):821-33. PubMed ID: 10875443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin is increased in the nucleus accumbens in Huntington's disease.
    Beal MF; Bird ED; Langlais PJ; Martin JB
    Neurology; 1984 May; 34(5):663-6. PubMed ID: 6143284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nucleus basalis lesions on cerebral cortical concentrations of corticotropin-releasing hormone (CRH)-like immunoreactivity in the rat.
    Millard WJ; Arendash GW; Dunn AJ; Meyer EM
    Neurosci Lett; 1990 May; 113(2):233-9. PubMed ID: 2377321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
    Marshall PE; Landis DM; Zalneraitis EL
    Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study.
    Waeber C; Palacios JM
    Neuroscience; 1989; 32(2):337-47. PubMed ID: 2531301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoreactive corticotropin-releasing hormone, growth hormone-releasing hormone, somatostatin, and peptide histidine methionine are present in adrenal pheochromocytomas, but not in extra-adrenal pheochromocytoma.
    Sasaki A; Yumita S; Kimura S; Miura Y; Yoshinaga K
    J Clin Endocrinol Metab; 1990 Apr; 70(4):996-9. PubMed ID: 1969422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease.
    Pittaway KM; Reynolds GP; Emson PC
    J Neurochem; 1984 Sep; 43(3):878-80. PubMed ID: 6235325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.
    Mann DM; Oliver R; Snowden JS
    Acta Neuropathol; 1993; 85(5):553-9. PubMed ID: 8493863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.
    Aylward EH; Brandt J; Codori AM; Mangus RS; Barta PE; Harris GJ
    Neurology; 1994 May; 44(5):823-8. PubMed ID: 8190282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.